A detailed history of Charles Schwab Investment Management Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 260,120 shares of KROS stock, worth $4.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260,120
Previous 227,628 14.27%
Holding current value
$4.35 Million
Previous $10.4 Million 45.21%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$41.68 - $58.07 $1.35 Million - $1.89 Million
32,492 Added 14.27%
260,120 $15.1 Million
Q2 2024

Aug 12, 2024

BUY
$44.58 - $66.89 $885,804 - $1.33 Million
19,870 Added 9.56%
227,628 $10.4 Million
Q1 2024

May 08, 2024

BUY
$41.26 - $70.48 $1.08 Million - $1.85 Million
26,180 Added 14.42%
207,758 $13.8 Million
Q4 2023

Feb 06, 2024

BUY
$27.12 - $41.05 $125,430 - $189,856
4,625 Added 2.61%
181,578 $7.22 Million
Q3 2023

Nov 08, 2023

BUY
$31.57 - $43.02 $920,833 - $1.25 Million
29,168 Added 19.74%
176,953 $5.64 Million
Q2 2023

Aug 09, 2023

BUY
$37.26 - $51.01 $559,533 - $766,017
15,017 Added 11.31%
147,785 $5.94 Million
Q1 2023

May 11, 2023

SELL
$41.44 - $59.32 $24,200 - $34,642
-584 Reduced 0.44%
132,768 $5.67 Million
Q4 2022

Feb 13, 2023

BUY
$39.45 - $51.77 $443,260 - $581,687
11,236 Added 9.2%
133,352 $6.4 Million
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $554,359 - $800,032
19,941 Added 19.52%
122,116 $4.6 Million
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $37,353 - $96,202
1,435 Added 1.42%
102,175 $2.82 Million
Q1 2022

May 13, 2022

BUY
$42.12 - $59.36 $101,256 - $142,701
2,404 Added 2.44%
100,740 $5.48 Million
Q4 2021

Feb 11, 2022

SELL
$36.95 - $62.89 $7,685 - $13,081
-208 Reduced 0.21%
98,336 $5.75 Million
Q3 2021

Nov 16, 2021

BUY
$29.27 - $43.71 $584,229 - $872,451
19,960 Added 25.4%
98,544 $3.9 Million
Q2 2021

Aug 16, 2021

BUY
$42.4 - $70.11 $859,617 - $1.42 Million
20,274 Added 34.77%
78,584 $3.34 Million
Q1 2021

May 17, 2021

BUY
$54.0 - $75.28 $139,158 - $193,996
2,577 Added 4.62%
58,310 $3.59 Million
Q4 2020

Feb 16, 2021

BUY
$36.0 - $82.74 $427,824 - $983,282
11,884 Added 27.1%
55,733 $3.93 Million
Q3 2020

Nov 13, 2020

BUY
$27.04 - $62.21 $11,951 - $27,496
442 Added 1.02%
43,849 $1.69 Million
Q2 2020

Aug 14, 2020

BUY
$20.08 - $40.39 $871,612 - $1.75 Million
43,407 New
43,407 $1.63 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $430M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.